Deals For Genetic Data Raise Issues of Privacy, Sharing
By John Lauerman and Makiko Kitamura,
Bloomberg
| 01. 14. 2015
Untitled Document
In three recent deals, drugmakers are betting that personal genetic maps will finally fulfill their early promise to unlock secrets and cure diseases.
At the same time, the agreements revived questions about privacy protections and how useful personal genetic data will prove to be.
Roche Holding AG (RHHBY) committed $1 billion to take control of Foundation Medicine Inc. (FMI), which sequences genes of cancer patients, aiming to customize treatment. Roche’s Genentech unit said it would pay as much as $60 million for access to 23andMe Inc.’s data on customers with Parkinson’s disease. And Pfizer Inc. (PFE) reached a deal that will allow the drugmaker to analyze personal genetic information from 650,000 23andMe customers, without giving terms.
The pacts, together with 23andMe’s announcement that it will enter into partnerships with eight other companies this year, boosted confidence in the commercial value of gene mapping. Since the first draft of a full human genome was deciphered in 2001, researchers have predicted breakthroughs in understanding the origins of disease, only to be frustrated as business developed slowly and regulatory issues...
Related Articles
By Darren Incorvaia, Fierce Biotech | 07.16.2026
Jennifer Doudna, Ph.D., the Nobel Laureate best known for co-inventing the CRISPR system that has become the foundation for gene editing, is dipping her toes into a new, buzzy field: AI-powered protein design.
In a new paper, published today...
By Risa Cromer, The Conversation | 07.17.2026
By Emily Packard Dawson and Lainie Friedman Ross , The Hastings Center for Bioethics | 07.16.2026
Major news outlets recently reported – based on a bioRxiv preprint – that scientists had edited genes in human embryos with “startling precision.” The scientists’ decision to release this work ahead of peer review, coupled with the extensive media coverage...
Media coverage of recent developments in embryo gene editing might seem to suggest that gene-edited babies are close to becoming a reality. As tech billionaires eager to profit off of techno-eugenics invest in “designer baby” technologies, attempts to normalize heritable genome editing – which remains unsafe and raises significant ethical and societal concerns – are especially dangerous. It’s worth taking a closer look at these developments and what they mean, in a way that pushes back on narratives normalizing the...
